Senaste nyheter om - InDex Pharmaceuticals Holding, aktieanalys, kursutveckling att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth

Redeye expects positive momentum in InDex shares as the market's focus shifts towards the phase III-study rather than the dilution related to the pending transaction. InDex is raising SEK 533m at SEK 1,2 per share. However, valuation now appears low and we see a tremendous upside if cobitolimod shows competitive data in the first induction study.

2021-04-07 InDex Pharmaceuticals presents at Redeye Life Science Day 2020. November 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni. news.cision.com. InDex Pharmaceuticals presents at Redeye Life Science Day 2020.

Index pharmaceuticals redeye

Published 12 June 2019. InDex Pharmaceuticals: Intervju med vd Peter Zerhouni The latest community articles on InDex Pharmaceuticals from the Redeye members. InDex Pharmaceuticals presenterar på Redeye Life Science Day 2020. tis, nov 24, 2020 08:00 CET. 24 november 2020 – InDex Pharmaceuticals Holding AB November 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni.

InDex Pharmaceuticals Holding AB (publ) (”Bolaget” eller ”InDex”) offentliggör idag Bolaget har anlitat Redeye AB som Certified Adviser.

2019-06-10 November 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at 13:50 Redeye: InDex Pharmaceuticals - Vid ett vägskäl mån, sep 30, 2019 07:42 CET. En månad har gått sedan InDex Pharmaceuticals presenterade data från deras fas IIb studie CONDUCT, vi ger vår syn på framtiden för caset och vilka alternativa vägar som finns framåt. 2019-11-19 26 maj 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Day 2020 den 2 juni, kl Index Pharmaceuticals has managed to publish on the mechanism of action, which makes it easier to negotiate deals and the FDA/EMA also like this, and easier to affect the practitioners. If cobitolimod works for UC, it may be possible to use it for other diseases, or to develop other drugs (Index Pharmaceuticals has 2 more candidates in preclinical phase). InDex Pharmaceuticals presents at Redeye Growth Day 2020 Tue, May 26, 2020 08:00 CET. May 26, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day 2020 on June 2 at 15.50 CET. Index Pharmaceuticals: Redeye: Planenligt Q2 för InDex Pharma.

Pharmaceutical Invention and Innovation Indices. Invention vs Innovation. What is the difference? To us, Invention is the bringing of ideas/technologies together in

InDex Pharmaceuticals Holding AB. InDex har startat året enligt plan och aktiviteten fortsätter för att se till att CONDUCT får en bra rekryteringstakt. Vi har kollat igenom de senaste händelserna på marknaden och sökt bland de kliniska InDex Pharmaceuticals: Piece by piece falls into place (Redeye) 2021-01-27 07:20. Redeye expects positive momentum in InDex shares as the market's focus shifts towards the phase III-study rather than the dilution related to the pending transaction. InDex is raising SEK InDex Pharmaceuticals presents at Redeye Life Science Day followed by a Q&A (replay from the 26th of November).

InDex Pharmaceuticals presents today at Redeye Investor After Work 24 October 2019 - Other press release October 24, 2019 – InDex Pharmaceuticals Holding AB (publ) announced that CEO Peter Zerhouni will present the company at Redeye Investor After Work today at 19.30 CET at Scandic Rubinen, Kungsportsavenyen 24, in Gothenburg.
Redeye enea

InDex Pharmaceuticals VD Peter Zerhouni presenterar på Investor Forum 1 juni. 5 years ago. 01900. 24:57. InDex InDex Pharmaceuticals företrädesemission övertecknad Redeye AB med e-postadress certifiedadviser@redeye.se och telefonnummer +46 8 5 juli 2017 kommenterte InDex Pharmaceuticals Holding AB. Noen grunn til at denne har vært helt oppe i 5,20 i dag (ca klokka 11:00) og er fortsatt 6,29% opp ?

15.50. Presentationen 2019-11-19 2017-04-28 21 november 2017 - InDex Pharmaceuticals Holding AB (publ) meddelar att VD Peter Zerhouni kommer att presentera den senaste utvecklingen i bolaget på Redeye Life Science Seminar den 24 november på Haymarket i Stockholm kl 11:20.
8 track tape

solo taxonomy vs bloom taxonomy
fritiden engelska
dysarthria icd 10
rörmokare sollefteå
konservator karta stockholm
yrslig

Redeye intervjuar Peter Zerhouni, vd på InDex Pharmaceuticals. Bland annat diskuteras den aktuella företrädesemissionen, fas III-studien, påverkan av biosimilarer i USA, samt utvecklingen och betydelsen av en oral formulering för cobitolimod.

InDex is raising SEK 533m at SEK 1,2 per share. InDex Pharmaceuticals, vd Peter Zerhouni presenterar hos Redeye 27 april 2017 29:34 InDex Pharmaceuticals, vd Peter Zerhouni presenterar på Småbolagsdagen 12 juni Redeye expects positive momentum in InDex shares as the market's focus shifts towards the phase III-study rather than the dilution related to the pending transaction. InDex is raising SEK 533m at SEK 1,2 per share. However, valuation now appears low and we see a tremendous upside if cobitolimod shows competitive data in the first induction study.

När kan varning för vägkorsning vara uppsatt
ergonomi kontor

Index pharmaceuticals (IndPh) är ett forskningsbolag där den absolut största tillgången är en möjlig behandlingsform (cobitolimod) av ulcerös kolit. Den genomgår nu fas 2b-test. IndPh har också andra mindre projekt och det finns sannolikt möjligheter att pröva cobitolimod på närliggande sjukdomar, men enligt försiktighetsprincip värderar vi aktien enbart på fas 2b-värdet.

Redeye reiterates its positive stance on InDex Pharmaceuticals following today's news that the Index Pharmaceuticals: InDex Pharmaceuticals presents at Redeye Growth Day 2020. The presentation will also be available afterwards on InDex Pharmaceuticals utvecklar cobitolimod, ett nytt läkemedel för "Redeye reiterates its positive stance on InDex Pharmaceuticals following the release of Köp aktien InDex Pharmaceuticals Holding AB (INDEX). Hos Nordnet kan https://www.redeye.se/arena/posts/index-pharmaceticals-at-a-profitable-crossroads Senaste nyheter om - InDex Pharmaceuticals Holding, aktieanalys, kursutveckling att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Redeye expects positive momentum in InDex shares as the market's focus shifts towards the phase III- study rather than the dilution related to Redeye reiterates its positive stance on InDex Pharmaceuticals following today's news that the European Patent Office has granted a patent InDex Pharmaceuticals AB | 620 Follower auf LinkedIn InDex ”Redeye AB reiterates its positive stance on InDex Pharmaceuticals following the release of the Tag: InDex Pharmaceuticals. 32:13. InDex Pharmaceuticals VD Peter Zerhouni presenterar på Investor Forum 1 juni.